Evogene (EVGN)
NASDAQ:EVGN
Want to see EVGN full AI Analyst Report?
Earnings Data
Report Date
Aug 26, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.27Last Year’s EPS
-0.5Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call presented strong technology and pipeline progress — notable AI/Google collaborations, a rapidly growing pharma collaboration slate, and demonstrable iterative success in the Ag fungicide program — which are meaningful strategic achievements. However, these operational and R&D advances are contrasted by material near-term financial weakness: an ~87% revenue decline year-over-year, increased net loss driven largely by financing charges, the termination of a Bayer collaboration for biological reasons, and a modest cash balance that implies limited runway without further funding or cash inflows. Overall, business momentum on the technology and pipeline front is positive, but short-term financial and commercial metrics are weak and present risk.Company Guidance
Strategic Technology Partnerships and Platform Advancement
Expanded Campus AI capabilities via continued collaboration with Google (second collaboration announced Feb 2026) to integrate advanced AI agents, enabling automated extraction of insights from scientific literature, creation of proprietary datasets and building more accurate computational models — positioned to materially strengthen Evogene's technological leadership in small-molecule discovery.
Accelerating Pharma Collaboration Pipeline
Pharma division announced three new collaborations in Q1 2026 (Systasy Bioscience + Ludwig Maximilian University Hospital for neutrophil-driven hyperinflammatory diseases; Unravel Biosciences for demyelinating disorders / MS; Queensland University of Technology on chemotherapy resistance). Pharma effort launched in early 2025 and has grown to multiple high-potential partnerships within ~1 year, targeting large markets including a >$26 billion opportunity for demyelinating disorders.
Demonstrated Iterative Success in Ag Fungicide Discovery (Septoria Program)
AgPlenus internal Septoria fungicide program showed strong iterative improvement using ChemPass AI: initial screen 440 candidates → 11 met enzymatic thresholds and 2 showed antifungal activity; second purchased set 164 → 38 enzymatic hits and 5 antifungal; later 27 novel compounds custom synthesized → 25 met enzymatic thresholds and 15 showed desired biological activity. This represents a dramatic improvement in hit rates and validates the AI-driven experimental cycle.
Confirmed Industry Validation and Prior Strategic Collaborations
Established strategic collaborations with major ag partners (previous partnerships with Bayer and Corteva) and multiple biotech/academic partners — these collaborations validate Evogene's discovery capabilities and support commercialization pathways.
Cash Position and Near-Term Cash Inflows
Consolidated cash, cash equivalents and short-term deposits of approximately $13.1 million as of March 31, 2026; Q1 consolidated cash usage approximately $2.8 million. February 2026 warrant inducement transaction generated gross proceeds of approximately $3.4 million (before fees) and Lavie/Biomica approved dividend distributions ($4.25M and $2.7M respectively) that are expected to provide additional cash to shareholders/subsidiaries.
Reduced Operating and R&D Spend vs Prior Year
Research & development expenses decreased to approximately $1.8 million in Q1 2026 from $2.5 million in Q1 2025 (approximately 28% decline), and certain operating expense reductions were realized following scaling down of non-core subsidiaries.
EVGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
EVGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 20, 2026 | $0.74 | $0.72 | -3.36% |
Mar 05, 2026 | $0.84 | $0.79 | -6.21% |
Nov 20, 2025 | $1.17 | $1.08 | -7.69% |
Aug 19, 2025 | $1.33 | $1.27 | -4.51% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Evogene (EVGN) report earnings?
Evogene (EVGN) is schdueled to report earning on Aug 26, 2026, TBA (Confirmed).
What is Evogene (EVGN) earnings time?
Evogene (EVGN) earnings time is at Aug 26, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EVGN EPS forecast?
EVGN EPS forecast for the fiscal quarter 2026 (Q2) is -0.27.